Halozyme Therapeutics Inc. (NASDAQ:HALO) Given Consensus Rating of “Buy” by Analysts
Halozyme Therapeutics Inc. (NASDAQ:HALO) has earned an average rating of “Buy” from the eight analysts that are currently covering the stock. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $16.13.
A number of research analysts have issued reports on the stock. Piper Jaffray Cos. boosted their price objective on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the company an “overweight” rating in a research report on Friday, September 16th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, September 8th.
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Fund Advisors increased its stake in shares of Halozyme Therapeutics by 2.5% in the first quarter. BlackRock Fund Advisors now owns 4,302,729 shares of the biopharmaceutical company’s stock valued at $40,747,000 after buying an additional 104,120 shares during the period. BlackRock Group LTD increased its stake in shares of Halozyme Therapeutics by 11.2% in the first quarter. BlackRock Group LTD now owns 128,945 shares of the biopharmaceutical company’s stock valued at $1,221,000 after buying an additional 12,956 shares during the period. Bellevue Group AG purchased a new stake in shares of Halozyme Therapeutics during the first quarter valued at approximately $3,011,000. California State Teachers Retirement System increased its stake in shares of Halozyme Therapeutics by 1.4% in the second quarter. California State Teachers Retirement System now owns 228,638 shares of the biopharmaceutical company’s stock valued at $1,973,000 after buying an additional 3,260 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its stake in shares of Halozyme Therapeutics by 8.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 66,700 shares of the biopharmaceutical company’s stock valued at $562,000 after buying an additional 5,000 shares during the period. 80.41% of the stock is currently owned by institutional investors.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/halozyme-therapeutics-inc-nasdaqhalo-given-consensus-rating-of-buy-by-analysts.html
Halozyme Therapeutics (NASDAQ:HALO) traded up 2.52% on Monday, hitting $12.22. 415,831 shares of the company were exchanged. Halozyme Therapeutics has a 52 week low of $6.96 and a 52 week high of $18.65. The stock’s market capitalization is $1.56 billion. The company has a 50 day moving average price of $11.11 and a 200-day moving average price of $10.07.
Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.06. The business had revenue of $33.30 million for the quarter, compared to the consensus estimate of $29.94 million. Halozyme Therapeutics had a negative net margin of 44.90% and a negative return on equity of 234.15%. The company’s quarterly revenue was down 23.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.02 EPS. On average, equities analysts expect that Halozyme Therapeutics will post ($0.91) earnings per share for the current fiscal year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.